Related references
Note: Only part of the references are listed.Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
Shuofeng Yuan et al.
NATURE (2021)
Multiple Myeloma: Heterogeneous in Every Way
Anais Schavgoulidze et al.
CANCERS (2021)
Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
Hedwig M. Blommestein et al.
JAMA NETWORK OPEN (2021)
Identification and Characterization of Multiple Myeloma Stem Cell-Like Cells
Wancheng Guo et al.
CANCERS (2021)
Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells
Harish Kumar et al.
HAEMATOLOGICA (2020)
Direct to Drug screening as a precision medicine tool in multiple myeloma
Cecilia Bonolo de Campos et al.
BLOOD CANCER JOURNAL (2020)
In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma
Amit Kumar Mitra et al.
BLOOD CANCER JOURNAL (2020)
BEX2 suppresses mitochondrial activity and is required for dormant cancer stem cell maintenance in intrahepatic cholangiocarcinoma
Keiichi Tamai et al.
SCIENTIFIC REPORTS (2020)
Molecular functions of brain expressed X-linked 2 (BEX2) in malignancies
Ali Naderi
EXPERIMENTAL CELL RESEARCH (2019)
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
Ola Landgren et al.
LEUKEMIA (2019)
Disulfiram/copper targets stem cell-like ALDH+ population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway
Na Jin et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma
Anna Bianchi-Smiraglia et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
O. Landgren et al.
JOURNAL OF INTERNAL MEDICINE (2017)
Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line
Ipek Z. Durusu et al.
LEUKEMIA RESEARCH (2017)
A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
A. K. Mitra et al.
BLOOD CANCER JOURNAL (2017)
Myeloma today: Disease definitions and treatment advances
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors
A. K. Mitra et al.
LEUKEMIA (2016)
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment (vol 127, pg 713, 2016)
P. G. Richardson et al.
BLOOD (2016)
Multiple Myeloma: Diagnosis and Treatment
S. Vincent Rajkumar et al.
MAYO CLINIC PROCEEDINGS (2016)
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide
Deepika S. Das et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Brain-expressed X-linked 2 Is Pivotal for Hyperactive Mechanistic Target of Rapamycin (mTOR)-mediated Tumorigenesis
Zhongdong Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
Reinaldo Franqui-Machin et al.
ONCOTARGET (2015)
Anti-leprosy drug clofazimine inhibits growth of triple-negative breast cancer cells via inhibition of canonical Wnt signaling
A. V. Koval et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Causal analysis approaches in Ingenuity Pathway Analysis
Andreas Kraemer et al.
BIOINFORMATICS (2014)
ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma
W. Zhou et al.
LEUKEMIA (2014)
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Stress-induced self-cannibalism: on the regulation of autophagy by endoplasmic reticulum stress
Shane Deegan et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2013)
New Strategies in the Treatment of Multiple Myeloma
Nikhil C. Munshi et al.
CLINICAL CANCER RESEARCH (2013)
Systematic review of clofazimine for the treatment of drug-resistant tuberculosis
M. Gopal et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2013)
Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
Lisa Vincenz et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
Yuan Xiao Zhu et al.
LEUKEMIA & LYMPHOMA (2013)
Clonogenic Multiple Myeloma Cells have Shared Stemness Signature Associated with Patient Survival
Renji Reghunathan et al.
ONCOTARGET (2013)
Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells
Luigi Leanza et al.
EMBO MOLECULAR MEDICINE (2012)
Genetic variations in multiple myeloma II: association with effect of treatment
Annette Vangsted et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Clofazimine: current status and future prospects
Moloko C. Cholo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Molecular pathogenesis of multiple myeloma and its premalignant precursor
W. Michael Kuehl et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
CD19-CD45low/-CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
D. Kim et al.
LEUKEMIA (2012)
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2011)
Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
Constantine S. Mitsiades et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
William Matsui et al.
CANCER RESEARCH (2008)
Multiple myeloma cancer stem cells
Carol Ann Huff et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Presence of Hoechst low side populations in multiple myeloma
Yen S. Loh et al.
LEUKEMIA & LYMPHOMA (2008)
Clofazimine Inhibits Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T Lymphocytes
Yunzhao R. Ren et al.
PLOS ONE (2008)
BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-κB inhibition of apoptosis in breast cancer cell lines
Ali Naderi et al.
CANCER RESEARCH (2007)
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma
M. E. Prince et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Mediators of endoplasmic reticulum stress-induced apoptosis
Eva Szegezdi et al.
EMBO REPORTS (2006)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
A regulatory link between ER-associated protein degradation and the unfolded-protein response.
R Friedlander et al.
NATURE CELL BIOLOGY (2000)
Share Paper
